zamtocabtagene autoleucel (MB-CART2019.1) Clinical Trials

2 actively recruiting trials across 1 location

No change since June 2026

Pipeline

Phase 2: 2

Top Sponsors

Miltenyi Biomedicine GmbH2

Indications

Cancer2
Transplant-ineligible 2nd Line DLBCL1
Primary Mediastinal B-cell Lymphoma (PMBCL)1
High-grade B-cell Lymphoma (HGBCL)1
Transformed Lymphoma1

Other1 trial

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

Phase 2

Birmingham, Alabama1 trial

DALY II USA/ MB-CART2019.1 for DLBCL

University of Alabama at Birmingham

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.